HomeCompareWRK vs ABBV

WRK vs ABBV: Dividend Comparison 2026

WRK yields 2.35% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $82.0K in total portfolio value
10 years
WRK
WRK
● Live price
2.35%
Share price
$51.51
Annual div
$1.21
5Y div CAGR
-36.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.4K
Annual income
$2.67
Full WRK calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — WRK vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWRKABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WRK + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WRK pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WRK
Annual income on $10K today (after 15% tax)
$199.67/yr
After 10yr DRIP, annual income (after tax)
$2.27/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,053.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WRK + ABBV for your $10,000?

WRK: 50%ABBV: 50%
100% ABBV50/50100% WRK
Portfolio after 10yr
$61.3K
Annual income
$12,387.22/yr
Blended yield
20.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

WRK
Analyst Ratings
11
Buy
12
Hold
3
Sell
Consensus: Hold
Price Target
$49.75
-3.4% upside vs current
Range: $34.00 — $60.00
Altman Z
1.4
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WRK buys
0
ABBV buys
0
No recent congressional trades found for WRK or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWRKABBV
Forward yield2.35%3.06%
Annual dividend / share$1.21$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-36.3%40.6%
Portfolio after 10y$20.4K$102.3K
Annual income after 10y$2.67$24,771.77
Total dividends collected$413.00$61.0K
Payment frequencyquarterlyquarterly
SectorMaterialsHealthcare
Analyst consensusHoldBuy
Analyst price target$49.75$256.15

Year-by-year: WRK vs ABBV ($10,000, DRIP)

YearWRK PortfolioWRK Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,850$149.64$11,550$430.00$700.00ABBV
2$11,706$96.65$13,472$627.96$1.8KABBV
3$12,587$62.08$15,906$926.08$3.3KABBV
4$13,508$39.74$19,071$1,382.55$5.6KABBV
5$14,479$25.39$23,302$2,095.81$8.8KABBV
6$15,509$16.20$29,150$3,237.93$13.6KABBV
7$16,605$10.33$37,536$5,121.41$20.9KABBV
8$17,774$6.58$50,079$8,338.38$32.3KABBV
9$19,022$4.20$69,753$14,065.80$50.7KABBV
10$20,356$2.67$102,337$24,771.77$82.0KABBV

WRK vs ABBV: Complete Analysis 2026

WRKMaterials

WestRock Company, together with its subsidiaries, provides fiber-based paper and packaging solutions in North America, South America, Europe, Asia, and Australia. It operates through two segments, Corrugated Packaging and Consumer Packaging. The Corrugated Packaging segment produces containerboards, corrugated sheets, corrugated packaging, and preprinted linerboards to consumer and industrial products manufacturers, and corrugated box manufacturers. It also provides structural and graphic design, engineering services and custom, and proprietary and standard automated packaging machines, as well as turn-key installation, automation, line integration, and packaging solutions; distributes corrugated packaging materials and other specialty packaging products, including stretch films, void fills, carton sealing tapes, and other specialty tapes; operates recycling facilities that collect, sort, grade, and bale recovered paper; and provides lithographic laminated packaging products, as well as contract packing services. The Consumer Packaging segment manufactures and sells folding cartons that are used to package food, paper, beverages, dairy products, tobacco, confectionery, health and beauty, other household consumer, and commercial and industrial products; and express mail packages for the overnight courier industry. It also offers inserts and labels, as well as rigid packaging and other printed packaging products, such as transaction cards, brochures, product literature, marketing materials, and grower tags and plant stakes for the horticultural market; and secondary packages and paperboard packaging for over-the-counter and prescription drugs. In addition, this segment manufactures and sells solid fiber and corrugated partitions, and die-cut paperboard components principally to glass container manufacturers and the automotive industry, as well as producers of beer, food, wine, spirits, cosmetics, and pharmaceuticals. WestRock Company is based in Atlanta, Georgia.

Full WRK Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this WRK vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WRK vs SCHDWRK vs JEPIWRK vs OWRK vs KOWRK vs MAINWRK vs JNJWRK vs MRKWRK vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.